Financial Performance - Total revenue for 2022 was CNY 8,115,804,648.33, a decrease of 11.10% compared to 2021[28]. - Net profit attributable to shareholders was CNY 539,570,083.23, down 48.38% from the previous year[28]. - The company reported a net cash flow from operating activities of CNY 520,603,490.03, a decline of 54.20% year-on-year[28]. - The total assets at the end of 2022 were CNY 12,432,616,205.07, a decrease of 0.80% from the previous year[28]. - The net assets attributable to shareholders increased by 5.48% to CNY 9,259,881,857.33[28]. - The overall operating income decreased by 11.10% to CNY 8,115,804,648.33 compared to the previous year[81]. - Basic earnings per share decreased by 48.62% to CNY 0.56 in 2022 from CNY 1.09 in 2021[129]. - Diluted earnings per share also fell by 48.62% to CNY 0.56 in 2022 compared to CNY 1.09 in 2021[129]. - The weighted average return on equity dropped by 6.65 percentage points to 5.99% in 2022 from 12.64% in 2021[129]. Research and Development - R&D expenses totaled CNY 809,279,317.22, accounting for 9.97% of total revenue[17]. - The company applied for 24 patents during the reporting period, including 21 invention patents, and has a total of 686 invention patent applications as of December 31, 2022[48]. - The company reported a total R&D investment of 15,664 million RMB for the anti-Her2-ADC project, which accounted for 1.93% of total revenue, reflecting a decrease of 15.47% compared to the previous year[169]. - The R&D investment for the innovative research on key intermediates of raw materials reached 2,297 million RMB, showing a significant increase of 890.21% compared to the previous year[169]. - The company has a strong focus on ensuring that intangible assets can generate economic benefits, supported by sufficient technical and financial resources[158]. - The company follows a research and development accounting policy where expenses during the research phase are recognized in the current period, while development phase expenses can be recognized as intangible assets if certain criteria are met[158]. Sales and Marketing - The company's sales revenue for life nutrition products reached CNY 384,105.80 million, accounting for 47.33% of total revenue, a year-on-year decrease of 18.91%[75]. - Pharmaceutical manufacturing generated sales of CNY 201,622.05 million, representing 24.84% of total revenue, with a year-on-year decline of 3.00%[75]. - Pharmaceutical commerce achieved sales of CNY 213,660.98 million, making up 26.33% of total revenue, down 4.99% year-on-year[75]. - The company has established a comprehensive marketing network covering over 25,000 pharmacies, achieving effective coverage in all provinces except Tibet[183]. - The company’s marketing strategy emphasizes compliance and efficiency, aiming to enhance product sales through scientific marketing methods[175]. - The company has established long-term partnerships with major pharmaceutical companies for raw material exports, ensuring stable sales channels[182]. Production and Operations - The company is advancing the production of vitamin E precursor projects, achieving self-sufficient production of key raw materials by the end of 2022[47]. - The company has implemented a safety production management system and established a "no waste park" initiative to enhance operational efficiency[45]. - The company is focusing on enhancing its product structure and industry chain layout in response to market challenges[47]. - The company is transitioning to "Industry 4.0" in the pharmaceutical sector, implementing modern and digital control systems in production[68]. - The company has established long-term strategic partnerships with reputable domestic and international distributors, enhancing its marketing network[68]. Market Trends and Challenges - The company has made significant advancements in the vitamin industry, despite challenges such as rising costs and decreased demand in the feed and breeding sectors[51]. - The sales of the main products, such as Vitamin E and A, have declined due to international market conditions and price drops[76]. - The company is actively responding to regulatory changes aimed at accelerating the approval process for innovative drugs, which could positively impact future product launches[135]. Investments and Acquisitions - The total investment amount for the reporting period was 346.30 million RMB, representing an increase of 91.14 million RMB or 35.72% compared to the previous year's investment of 255.16 million RMB[192]. - The company increased its capital in Fangyuanxin Biological by 200 million RMB, raising its registered capital from 50 million RMB to 250 million RMB[192]. - The company acquired 100% equity of Shilitaihe for 6.3 million RMB, completing the transfer of control by May 31, 2022[192]. - The company is focused on expanding its investments in biotechnology and pharmaceuticals, as evidenced by the capital increases in its subsidiaries[192]. - The company is actively pursuing strategic acquisitions to enhance its market position and technological capabilities[192].

Financial Performance - The net profit for Q1 2023 was CNY 84,072,216.08, a decrease of 60.9% compared to CNY 214,844,440.33 in Q1 2022[17] - The total revenue for Q1 2023 was CNY 105,302,495.52, down from CNY 268,017,651.01 in the same period last year, indicating a decline of 60.7%[17] - The total comprehensive income for Q1 2023 was CNY 85,331,152.98, down from CNY 210,743,400.09 in Q1 2022[17] - The net profit attributable to shareholders was ¥113,551,849.15, down 56.42% year-over-year, primarily due to a significant decline in the selling price of the main product, VA[24] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥98,141,772.45, a decrease of 61.55% compared to the previous year[20] - The basic and diluted earnings per share were both ¥0.12, reflecting a decline of 55.56% year-over-year[20] - The comprehensive income attributable to the parent company's owners was ¥114,760,535.24, down from ¥256,763,499.85 in the same period last year[34] Shareholder Information - The company reported a total of 68,061 common shareholders at the end of the reporting period[9] - The total number of shares held by the largest shareholder, New Changxing Changxin Investment Development Co., Ltd., was 208,192,361, representing 21.57% of total shares[9] Assets and Liabilities - The total liabilities amounted to CNY 2,660,022,342.62, a slight decrease from CNY 2,722,757,157.71 in the previous period[15] - The total equity attributable to shareholders of the parent company was CNY 9,401,601,058.23, an increase from CNY 9,259,881,857.33[15] - The total current assets as of March 31, 2023, amounted to CNY 5,607,508,474.35, slightly down from CNY 5,654,960,631.32 at the end of 2022[40] - The total non-current assets increased to CNY 6,875,763,833.60 from CNY 6,777,655,573.75 at the end of 2022[41] - The total assets reached CNY 12,483,272,307.95, up from CNY 12,432,616,205.07 at the end of 2022[41] Cash Flow - The net cash flow from operating activities increased by 111.26% to ¥19,934,634.67, mainly due to a reduction in payments for raw materials[24] - In Q1 2023, the cash inflow from operating activities was CNY 1,923,099,171.73, a decrease of 7.04% from CNY 2,068,968,525.42 in Q1 2022[35] - The net cash flow from operating activities was CNY 19,934,634.67, compared to a net outflow of CNY -177,050,453.00 in the same period last year[48] - The cash outflow from investing activities was CNY 493,879,019.83, down from CNY 583,112,675.51 in Q1 2022[48] - The cash flow from financing activities resulted in a net outflow of CNY -7,214,513.92, compared to a net inflow of CNY 71,569,874.78 in the same period last year[48] - The company reported a decrease in cash received from operating activities, with a drop of CNY 133,769,353.69 compared to the previous year[48] - The company’s cash flow from investment activities showed a significant improvement, with a reduction in net outflow by CNY 214,484,790.54 year-over-year[48] Accounting Standards and Compliance - Zhejiang Pharmaceutical Co., Ltd. will implement new accounting standards starting in 2023, affecting the financial statements from the beginning of the year[50] - The board of directors announced the financial report on April 25, 2023, indicating a commitment to transparency and compliance with updated regulations[51] - The company is focused on enhancing its financial reporting practices to align with the latest accounting guidelines[50] - There are no adjustments reported for the first execution year of the new accounting standards, indicating stability in financial reporting[50] - The company aims to maintain its market position while adapting to new regulatory requirements[51] - Future financial outlook remains cautiously optimistic as the company navigates the changes in accounting standards[50] - The board emphasizes the importance of accurate financial data in strategic decision-making processes[51] - The implementation of new standards is expected to improve the overall quality of financial disclosures[50] - The company is committed to ongoing evaluation of its financial practices to ensure compliance and accuracy[51] - No significant changes in user data or market expansion strategies were disclosed during the call[51]

Financial Performance - The company's operating revenue for Q3 2022 was ¥2,006,205,112.46, a decrease of 8.56% compared to the same period last year[7]. - The net profit attributable to shareholders for Q3 2022 was ¥93,866,572.27, down 61.37% year-on-year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥57,410,371.09, a decline of 70.88% compared to the previous year[7]. - The basic earnings per share for Q3 2022 was ¥0.10, reflecting a decrease of 60.00% year-on-year[10]. - The diluted earnings per share for Q3 2022 was also ¥0.10, down 60.00% from the same period last year[10]. - Total operating revenue for the first three quarters of 2022 was CNY 6,123,873,142.30, a decrease of 10.1% compared to CNY 6,811,651,988.14 in the same period of 2021[30]. - Net profit for the third quarter of 2022 was CNY 357,899,312.31, a decline of 47.8% from CNY 685,910,072.56 in the same quarter of 2021[33]. - Total comprehensive income for the period attributable to the parent company was CNY 482,860,926.55, down from CNY 742,419,297.12 in the same period last year, representing a decrease of approximately 34.9%[35]. - Basic and diluted earnings per share were both CNY 0.51, compared to CNY 0.78 in the previous year, reflecting a decline of 34.6%[35]. Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date was ¥141,215,952.32, a decrease of 68.84% compared to the previous year[10]. - Cash inflow from operating activities totaled CNY 6,410,825,337.82, down from CNY 7,051,753,669.29, a decline of approximately 9.1%[39]. - Cash outflow from operating activities was CNY 6,269,609,385.50, compared to CNY 6,598,619,416.76 in the previous year, showing a decrease of about 5%[39]. - The ending cash and cash equivalents balance was CNY 1,304,784,270.68, down from CNY 1,632,665,283.12, reflecting a decrease of approximately 20%[41]. - The company reported a tax refund of CNY 321,071,190.31, compared to CNY 213,805,121.98 in the previous year, marking an increase of about 50.1%[39]. Assets and Liabilities - Total assets at the end of the reporting period were ¥12,370,875,396.96, a decrease of 1.29% from the end of the previous year[10]. - The company's current assets totaled CNY 5,658,885,465.86, down from CNY 6,034,823,006.11, indicating a decrease of about 6.19%[25]. - Cash and cash equivalents were reported at CNY 1,304,784,270.68, a significant decrease from CNY 1,768,531,510.26, reflecting a decline of approximately 26.30%[21]. - The company's total liabilities decreased to CNY 5,658,885,465.86 from CNY 6,034,823,006.11, indicating a decline of approximately 6.19%[25]. - The company's total liabilities decreased to CNY 2,707,415,382.53 from CNY 3,349,948,357.08, indicating a reduction of 19.2%[28]. - The total equity attributable to shareholders increased to CNY 9,165,509,080.53, up from CNY 8,779,106,085.10, representing a growth of 4.4%[28]. - The minority interest increased to CNY 497,950,933.90 from CNY 402,925,398.05, reflecting a growth of 23.5%[30]. - The company's deferred income tax liabilities decreased to CNY 10,998,703.64 from CNY 20,830,017.00, a reduction of 47.3%[28]. Research and Development - The company reported a significant increase in new drug R&D expenses during the quarter, contributing to the decline in net profit[14]. - Research and development expenses for the first three quarters of 2022 were CNY 555,393,836.63, down 19.8% from CNY 692,647,517.23 in the same period of 2021[30]. - The company has no significant new product launches or technological developments reported during the quarter[19]. Operational Costs - Total operating costs for the first three quarters of 2022 were CNY 5,498,607,942.85, down from CNY 5,966,861,959.15, reflecting a reduction of 7.8%[30]. - The company reported a financial expense of CNY -37,178,071.08, compared to CNY 51,751,856.25 in the previous year, indicating a significant improvement[30].

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 4,117,668,029.84, a decrease of 10.83% compared to CNY 4,617,544,128.15 in the same period last year[25]. - The net profit attributable to shareholders of the listed company was CNY 390,587,728.16, down 23.06% from CNY 507,621,136.65 in the previous year[25]. - The net profit after deducting non-recurring gains and losses was CNY 380,737,753.77, a decrease of 18.35% compared to CNY 466,291,760.87 in the same period last year[25]. - The net cash flow from operating activities was negative CNY 8,310,209.08, a significant decline from CNY 458,457,262.86 in the previous year, representing a decrease of 101.81%[25]. - The total assets at the end of the reporting period were CNY 12,330,384,792.90, down 1.61% from CNY 12,531,979,840.23 at the end of the previous year[25]. - Basic earnings per share for the first half of 2022 were CNY 0.41, a decrease of 22.64% from CNY 0.53 in the same period last year[25]. - The weighted average return on net assets was 4.40%, down 1.94 percentage points from 6.34% in the previous year[25]. - The company reported a significant increase in sales of its star product, lutein chewable tablets, indicating strong growth in innovative health products[45]. Research and Development - The company has applied for 8 invention patents during the reporting period, with 3 domestic invention patents granted, bringing the total to 671 applied and 276 effective patents, including 94 international patents[44]. - The company has successfully completed the production process verification for the active pharmaceutical ingredient of moxifloxacin and has commenced normal production of both moxifloxacin and natural vitamin E since June 2022[46]. - The company is advancing the development of its biopharmaceutical ARX788, with over 100 cases enrolled in clinical trials for gastric cancer as of May 2022[45]. - The company reported a significant reduction in research and development expenses to CNY 355,076,062.82 from CNY 545,351,850.09, a decrease of 34.83%[150]. Market and Industry Position - The main business remains unchanged, focusing on life nutrition products, pharmaceutical manufacturing, and pharmaceutical commerce, with key products including synthetic vitamins E and A, and antibiotic raw materials[29]. - The pharmaceutical industry is expected to maintain stable growth despite challenges from the pandemic and geopolitical issues, with the company positioned to leverage its technological advancements and strong market presence[34]. - The company aims to enhance its core competitiveness through innovation, structural adjustments, and the establishment of a robust marketing network with long-term partnerships[37]. - The company’s pharmaceutical commerce segment primarily targets public hospitals, leveraging a standardized operation to gain market share[32]. Challenges and Risks - The company has faced increased logistics costs due to the pandemic, impacting supply chains and market demand[34]. - The company is facing risks related to rising production costs due to international transportation cost increases and raw material price surges caused by geopolitical tensions[71]. - The company emphasizes the importance of policy changes in the pharmaceutical industry, which significantly affect its operations and strategies[67]. - The company has established a COVID-19 response plan to ensure employee health and maintain orderly production operations amid ongoing pandemic challenges[71]. Environmental and Sustainability Initiatives - The company is committed to sustainable practices, including clean production and circular economy initiatives, to strengthen its market position globally[37]. - The company has implemented pollution control measures, ensuring all facilities are operating normally and achieving stable compliance with discharge standards[88]. - The company has introduced a hazardous waste incineration facility to reduce waste generation and lower energy consumption through resource utilization[88]. - The company is actively promoting energy conservation and carbon reduction initiatives, aligning with national policies on "dual control of energy consumption" and "carbon neutrality"[98]. Shareholder and Capital Management - The company did not propose any profit distribution plan or capital reserve transfer to increase share capital during the reporting period[7]. - The company launched a second phase of a restricted stock incentive plan, granting 6.8275 million shares to 495 incentive targets, aimed at attracting and retaining talent[49]. - The company approved the second phase of the restricted stock incentive plan at the extraordinary shareholders' meeting on January 20, 2022[78]. - The company reported a profit distribution of CNY -318,492,240.00 during the period[179]. Financial Position and Equity - The total owner's equity at the end of the period was CNY 9,333,967,729.87, reflecting an increase from the previous period[196]. - The total comprehensive income for the period amounted to CNY 478,849,806.37[193]. - The total capital stock remained unchanged at CNY 965,128,000.00 throughout the period[182]. - The total liabilities decreased to CNY 2,251,962,583.25 from CNY 2,320,042,743.61, indicating a reduction of 2.94%[148].

Financial Performance - The company's operating revenue for Q1 2022 was ¥2,184,192,085.97, representing a decrease of 8.99% compared to the same period last year[5]. - The net profit attributable to shareholders of the listed company was ¥260,543,171.58, down by 2.37% year-on-year[5]. - The company's net profit for the current period is 214,844,440.33 CNY, a decrease of 13.06% compared to 247,198,278.37 CNY in the previous period[30]. - Operating profit for the current period is 268,017,651.01 CNY, down from 308,026,139.32 CNY, reflecting a decline of 12.99%[30]. - Total profit for the current period is 265,496,150.42 CNY, compared to 300,909,376.92 CNY in the previous period, indicating a decrease of 11.76%[30]. - The total comprehensive income attributable to the parent company's owners is 256,763,499.85 CNY, down from 263,083,185.84 CNY, a decrease of 2.43%[36]. - The basic earnings per share for the current period is 0.27 CNY, unchanged from the previous period[36]. Cash Flow - The net cash flow from operating activities was negative at ¥177,050,453.00, a significant decline of 535.29% compared to the previous year[5]. - The company's cash flow from operating activities shows a net outflow of -177,050,453.00 CNY, contrasting with a net inflow of 40,674,099.24 CNY in the previous period[36]. - Cash inflow from financing activities totaled ¥209,945,450, an increase of 47.8% compared to ¥142,089,400 in the previous period[38]. - Net cash flow from financing activities was ¥71,569,874.78, up from ¥32,772,757.33, representing a growth of 118.5%[38]. - The company reported a net decrease in cash and cash equivalents of ¥371,317,777.23, compared to a decrease of ¥108,554,448.09 in the previous period[38]. Assets and Liabilities - Total assets at the end of the reporting period were ¥12,570,948,928.69, showing a slight increase of 0.31% from the end of the previous year[7]. - Total liabilities decreased to CNY 3,176,492,996.76 from CNY 3,349,948,357.08, a reduction of 5.2%[24]. - The company's equity attributable to shareholders increased to CNY 9,042,539,568.35 from CNY 8,779,106,085.10, reflecting a growth of 3.0%[26]. - Short-term borrowings decreased to CNY 150,142,400.00 from CNY 176,123,955.84, a decline of 14.7%[24]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 66,330[12]. - The largest shareholder, New Changxing Changxin Investment Development Co., Ltd., held 21.57% of the shares[13]. Operational Costs and Expenses - Total operating costs for Q1 2022 were CNY 1,884,014,155.71, down 10.7% from CNY 2,110,584,983.10 in Q1 2021[26]. - Research and development expenses in Q1 2022 amounted to CNY 172,997,815.13, a decrease of 32.3% compared to CNY 255,998,479.70 in Q1 2021[26]. - The company reported a decrease in interest income to 3,188,350.66 CNY from 3,597,606.80 CNY, a decline of 11.34%[30]. - Investment income for the current period significantly increased to 17,089,432.40 CNY from 3,905,500.84 CNY, marking a rise of 337.73%[30]. Other Financial Metrics - The weighted average return on net assets was 2.92%, a decrease of 0.5 percentage points compared to the previous year[5]. - The company did not conduct an audit for the quarterly report[5]. - The cash inflow from minority shareholders' investments was ¥12,089,400, which is included in the total cash inflow from financing activities[38]. - The cash inflow from operating activities totaled 2,068,968,525.42 CNY, down from 2,173,662,369.57 CNY, a decrease of 4.81%[36]. - The cash flow from operating activities was primarily impacted by complex domestic and international environments and rising raw material prices[9].

Financial Performance - The net profit attributable to the parent company's shareholders for 2021 was CNY 1,045,319,896.03, while the net profit for the parent company was CNY 1,458,646,166.63[7] - The company achieved operating revenue of 9,129,094,496.62 RMB in 2021, representing a year-on-year increase of 24.60%[24] - The net profit attributable to shareholders of the listed company was 1,045,319,896.03 RMB, an increase of 45.71% compared to the previous year[24] - The net profit after deducting non-recurring gains and losses was 982,333,727.83 RMB, reflecting a growth of 67.44% year-on-year[24] - The company's total assets reached 12,531,979,840.23 RMB at the end of 2021, up 19.35% from the end of 2020[24] - The basic earnings per share for 2021 was 1.09 RMB, a 45.33% increase from 0.75 RMB in 2020[24] - The weighted average return on equity increased to 12.64%, up 3.38 percentage points from the previous year[24] - The company reported a net cash flow from operating activities of 1,136,655,957.52 RMB, a decrease of 9.55% compared to 2020[24] - The total revenue reached ¥9,087,790,708.10, with a year-on-year increase of 24.59%[60] - The company reported a gross margin of 41.13% for total operations, a decrease of 0.60 percentage points compared to last year[60] Dividend and Earnings Distribution - The company plans to distribute a cash dividend of CNY 3.30 per 10 shares, totaling CNY 318,492,240.00, based on a total share capital of 96,512,800 shares as of April 26, 2022[7] - The retained earnings available for distribution to shareholders at the end of the period amounted to CNY 5,627,858,012.02 after accounting for the legal surplus reserve[7] Risk Management - The company has not identified any significant risks that could materially affect its operations during the reporting period[11] - The company has outlined potential risks and countermeasures in its future operations in the management discussion section[11] - The company has confirmed that there were no non-operating fund occupations by controlling shareholders or related parties[9] - The company has maintained compliance with decision-making procedures regarding external guarantees[9] Audit and Compliance - The report includes a standard unqualified audit opinion from Tianjian Accounting Firm[6] - The company has maintained a focus on supply chain stability and structural reforms amid challenges from the pandemic and rising raw material prices[33] Research and Development - The company has applied for 19 invention patents during the reporting period, with 17 domestic and 3 international patents granted, bringing the total to 663 applied and 273 effective patents as of December 2021[39] - The company is focusing on the development of biopharmaceuticals and aims to transition from a traditional pharmaceutical company to a leading global pharmaceutical enterprise[99] - The company is investing in research and development for new formulations and delivery methods for existing products, aiming to improve efficacy and patient compliance[110] - The company has a strong pipeline of new products, including innovative formulations for existing drugs, which are expected to drive future growth[110] Product Development and Market Expansion - The company has successfully passed the consistency evaluation for its injectable drugs, including Teicoplanin (0.2g) and Vancomycin (0.5g), and received drug registration certificates for several products, including Sitagliptin Phosphate Tablets (100mg, 50mg) and Levofloxacin Tablets (0.5g, 0.25g)[35] - The company has made significant progress in its ADC innovative drug projects, with the clinical trials for ARX788 for breast cancer nearing completion and ongoing trials for gastric cancer[38] - The company is actively pursuing new product development and has completed the optimization of the formulation process for Daptomycin[38] - The company is exploring opportunities for market expansion and potential acquisitions to enhance its competitive position in the pharmaceutical industry[110] Sales and Revenue Breakdown - The company's sales revenue for life nutrition products reached CNY 473.66 million, accounting for 51.89% of total revenue, with a year-on-year growth of 44.23%[55] - Pharmaceutical manufacturing achieved sales of CNY 207.85 million, representing 22.77% of total revenue, with a year-on-year increase of 2.04%[55] - The pharmaceutical commercial segment generated sales of CNY 224.88 million, making up 24.63% of total revenue, with a year-on-year growth of 14.50%[55] Cost and Expense Management - Operating costs rose to CNY 5.40 billion, reflecting a 26.06% increase compared to CNY 4.28 billion last year[57] - Research and development expenses increased by 47.75% to CNY 806.86 million, up from CNY 546.09 million[57] - The company reported a significant increase in non-current liabilities due within one year, rising to ¥450,495,000, a 125.06% increase compared to ¥200,165,000 in the previous period[14] Corporate Governance and Management Changes - The total pre-tax compensation for the board members and senior management during the reporting period amounted to ¥2,289.50 million[180] - The company has undergone significant changes in its board and management personnel, with multiple elections and appointments during the reporting period[199] - The company is committed to transparency in its remuneration policies, ensuring they are aligned with shareholder interests[198] Future Outlook and Strategic Goals - The company aims for a revenue target of 9.0 billion yuan and a profit target of 560 million yuan for 2022, acknowledging the uncertainty in achieving these goals due to external factors[164] - The company plans to enhance its product offerings in the fields of fat-soluble vitamins, polyunsaturated fatty acids, and carotenoids, while also entering the spice and food sectors[160] - The company is focusing on expanding its antibiotic product line, with significant sales volumes reported across various antibiotic categories[115]

Financial Performance - The company's operating revenue for Q3 2021 was CNY 2,194,107,859.99, representing a year-on-year increase of 15.42%[7] - The net profit attributable to shareholders for the same period was CNY 242,993,711.50, reflecting a growth of 25.58% compared to the previous year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 197,138,445.54, with a slight decrease of 0.01%[7] - The basic earnings per share for Q3 2021 was CNY 0.25, an increase of 25.00% year-on-year[10] - Total operating revenue for the first three quarters of 2021 reached CNY 6,811,651,988.14, an increase of 25.4% compared to CNY 5,429,552,436.20 in the same period of 2020[27] - The company's net profit for the current period reached ¥685,910,072.55, an increase from ¥590,636,841.80 in the previous period, representing a growth of approximately 16.5%[31] - Operating profit rose to ¥871,046,107.37 compared to ¥702,111,675.92, reflecting an increase of approximately 24.1%[31] - The total comprehensive income for the period was ¥677,041,003.36, up from ¥592,987,978.33, indicating a growth of around 14.2%[33] - Basic earnings per share improved to ¥0.78 from ¥0.65, representing an increase of approximately 20%[33] - The company reported a total revenue from sales of goods and services amounting to ¥6,708,787,005.05, compared to ¥5,641,252,469.38, which is an increase of approximately 18.9%[37] Assets and Liabilities - The total assets at the end of the reporting period amounted to CNY 11,935,108,371.46, up 13.66% from the end of the previous year[10] - The company's total assets as of September 30, 2021, amounted to CNY 11,935,108,371.46, compared to CNY 10,500,457,880.84 at the end of 2020, reflecting a growth of 13.7%[25] - Current assets totaled CNY 6,177,338,144.47, an increase of 20.7% from CNY 5,118,012,434.82 in the previous year[22] - The company's total liabilities reached CNY 3,013,648,506.07, an increase of 21.9% compared to CNY 2,470,417,073.24 in the previous year[26] - Total liabilities were CNY 2,470,417,073.24, indicating a consistent financial structure[44] - The total assets reached CNY 10,500,457,880.84, remaining stable compared to the previous reporting period[41] Shareholder Information - The equity attributable to shareholders reached CNY 8,456,476,483.36, marking a 10.19% increase compared to the previous year[10] - The equity attributable to shareholders of the parent company was CNY 8,456,476,483.36, compared to CNY 7,674,560,932.92, reflecting a growth of 10.1%[27] - The company reported a total of 72,001 common shareholders at the end of the reporting period[15] - The top shareholder, New Changxing Investment Development Co., Ltd., held 21.57% of the shares, totaling 208,192,361 shares[15] - Total equity attributable to shareholders reached approximately ¥7.67 billion[47] - The company holds a total equity of approximately ¥8.03 billion[47] Cash Flow - The net cash flow from operating activities for the year-to-date was CNY 453,134,252.53, down 39.19% year-on-year due to increased VAT and income tax payments[10][14] - Cash flow from operating activities generated ¥453,134,252.53, a decrease from ¥745,121,054.12 in the previous period, showing a decline of about 39.2%[37] - Cash inflow from financing activities amounted to CNY 1,007,323,382.00, down from CNY 1,409,690,000.00[39] - Net cash flow from financing activities was CNY 253,966,243.15, a recovery from CNY -84,546,086.90 in the prior period[39] - Cash flow from investment activities totaled CNY 1,713,157,896.85, an increase from CNY 1,240,192,904.22 in the previous period[39] - Net cash flow from investment activities was negative at CNY -688,013,409.58, compared to CNY -82,108,097.45 previously[39] Expenses - Total operating costs for the first three quarters of 2021 were CNY 5,966,861,959.15, up 25.0% from CNY 4,777,598,052.40 in the previous year[27] - Research and development expenses increased significantly to ¥692,647,517.23 from ¥395,225,544.71, marking a rise of about 75.4%[31] - Financial expenses increased to ¥51,751,856.25 from ¥33,846,511.02, which is an increase of about 52.9%[31] Other Financial Metrics - The company received government subsidies amounting to CNY 48,556,037.83 year-to-date, which are closely related to its normal business operations[11] - The company recorded a net loss from minority interests of ¥64,704,775.60, compared to a loss of ¥29,897,459.01 in the previous period, reflecting a worsening of approximately 116.5%[31] - Cash and cash equivalents stood at CNY 1,632,665,283.12, slightly up from CNY 1,628,915,874.50[22] - The company's cash and cash equivalents at the end of the period were CNY 1,632,665,283.12, slightly down from CNY 1,854,252,629.72[39] - Accounts receivable stood at CNY 1,622,780,758.78, an increase of 38.0% from CNY 1,175,094,128.67 in the previous year[22] - Inventory as of September 30, 2021, was CNY 1,638,677,291.56, up from CNY 1,479,961,797.93, indicating a growth of 10.7%[22]

股票代码：600216 股票简称：浙江医药 编号：临 2021-026 浙江医药股份有限公司 关于举行投资者接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据中国证券监督管理委员会浙江监管局下发的《浙江辖区上市公司投资者 接待日工作指引》的要求，为进一步提高公司治理水平，加强投资者关系管理， 增进公司与广大投资者的沟通和交流，公司定于 2021 年 6 月 16 日下午举行 投资者接待日活动。现将有关事项公告如下： 1、活动时间：2021 年 6 月 16 日（星期三）15:00-16:00 2、活动地点：绍兴滨海新城致远中大道 168 号浙江医药总部 2 号楼展厅 3、召开方式：现场沟通 4、参加人员：公司董事长、公司总裁、财务总监、董事会秘书及部分其他 高管（如有特殊情况，参与人员会有调整）。 届时将针对经营情况、发展战略、公司治理等投资者关心的问题与广大投资 者进行现场交流和沟通，同时广泛听取投资者的意见和建议。 为了更好地安排本次活动，请有意参与本次活动的投资者提前与公司董事会 办公室工作人员 ...

Financial Performance - Operating revenue for the period was CNY 2,399,934,853.19, representing a growth of 49.98% year-on-year[11] - Net profit attributable to shareholders was CNY 266,868,693.16, up 79.78% from the same period last year[11] - Basic earnings per share increased to CNY 0.28, an increase of 86.67% year-on-year[11] - The net profit after deducting non-recurring gains and losses was CNY 258,239,892.12, reflecting a significant increase of 157.89% year-on-year[11] - The company reported a net profit of CNY 4,858,657,393.81, up from CNY 4,535,485,577.05, representing an increase of approximately 7.1%[40] - Total operating revenue for Q1 2021 reached approximately $2.40 billion, a 49.99% increase from $1.60 billion in Q1 2020[45] - Net profit for Q1 2021 was approximately $247.20 million, representing an increase of 78.60% compared to $138.46 million in Q1 2020[47] - Total comprehensive income for the first quarter of 2021 was approximately CNY 323.17 million, compared to CNY 198.84 million in the same period of 2020, representing a year-over-year increase of 62.5%[53] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 10,950,209,798.47, an increase of 4.28% compared to the end of the previous year[11] - Total current assets amounted to CNY 5,351,705,315.93, compared to CNY 4,828,929,525.75, reflecting an increase of approximately 10.8%[39] - Total liabilities increased to CNY 2,248,486,021.77 from CNY 1,924,147,781.11, reflecting higher short-term borrowings[33] - Non-current assets totaled CNY 5,155,298,945.05, a slight increase from CNY 5,142,415,455.31, indicating a growth of about 0.3%[39] - The company’s total liabilities include short-term borrowings of $250,305,000.00 and accounts payable of $674,333,408.75[66] Cash Flow - The net cash flow from operating activities was CNY 40,674,099.24, a decrease of 76.70% compared to the previous year[11] - Cash received from tax refunds increased by 85.95% to ¥68,013,753.08, due to higher export tax rebates[23] - Cash flow from investment activities decreased by 42.47% to ¥168,264,972.62, due to reduced redemption of financial products[23] - Cash inflow from operating activities for the first quarter of 2021 was CNY 2.17 billion, compared to CNY 1.82 billion in the first quarter of 2020, indicating an increase of 19.4%[56] - Net cash flow from investing activities for the first quarter of 2021 was negative CNY 179.44 million, a decrease from a positive CNY 17.37 million in the first quarter of 2020[56] Shareholder Information - Total shareholders at the end of the reporting period reached 71,870, with the largest shareholder, New Changxing Investment Development Co., Ltd., holding 208,192,361 shares, representing 21.57%[17] - The total number of shares held by the top ten shareholders accounted for a significant portion of the company's equity, with the top two shareholders alone holding over 37%[17] Research and Development - Research and development expenses surged to 255,998,479.70, reflecting a 288.33% increase from 65,922,899.63 in the previous year, indicating a significant increase in R&D investment[20] - Research and development expenses surged to approximately $256.00 million in Q1 2021, a significant increase of 287.66% from $65.92 million in Q1 2020[45] Other Financial Metrics - The weighted average return on equity rose to 3.42%, an increase of 1.55 percentage points compared to the previous year[11] - The company reported a significant decrease in investment income, down 77.56% to 3,905,500.84, primarily due to the sale of part of its shares in Xianju Pharmaceutical in the previous year[20] - Income tax expenses increased by 66.31% to ¥53,711,098.55, attributed to higher total profit[23] - The company reported a significant increase in sales expenses, totaling approximately $309.17 million in Q1 2021, compared to $292.70 million in Q1 2020[45]

Financial Performance - The net profit attributable to shareholders for 2020 was CNY 717,399,564.70, while the net profit for the parent company was CNY 860,757,837.20[7]. - The company plans to distribute a cash dividend of CNY 2.30 per 10 shares, totaling CNY 220,409,115.00, based on a total share capital of 96,512.8 million shares[7]. - The retained earnings available for distribution to shareholders at the end of the year amounted to CNY 4,535,485,577.05[7]. - The company extracted 10% of the parent company's net profit as statutory surplus reserve, amounting to CNY 86,075,783.72, and an additional 5% as discretionary surplus reserve, totaling CNY 43,037,891.86[7]. - The company's operating revenue for 2020 was approximately ¥7.33 billion, representing a 4.02% increase from ¥7.04 billion in 2019[27]. - Net profit attributable to shareholders for 2020 was approximately ¥717.40 million, a significant increase of 109.29% compared to ¥342.77 million in 2019[27]. - The net profit after deducting non-recurring gains and losses was approximately ¥586.67 million, up 166.89% from ¥219.82 million in 2019[27]. - The net cash flow from operating activities reached approximately ¥1.26 billion, marking an increase of 180.99% from ¥447.25 million in 2019[27]. - Basic earnings per share for 2020 was ¥0.75, up 108.33% from ¥0.36 in 2019[28]. - The weighted average return on equity increased to 9.26%, up 4.82 percentage points from 4.44% in 2019[28]. - Total assets at the end of 2020 were approximately ¥10.50 billion, a 1.33% increase from ¥10.36 billion at the end of 2019[27]. - The company reported a total of ¥130.73 million in non-recurring gains for 2020, compared to ¥122.95 million in 2019[30]. Risk Management - There were no significant risks that materially affected the company's operations during the reporting period[11]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[9]. - The company has maintained compliance with decision-making procedures regarding external guarantees[9]. - The company emphasizes the importance of risk awareness regarding future plans and development strategies[8]. - The company faces risks from policy changes in the pharmaceutical industry, including drug price reductions due to healthcare cost control measures[154]. - The company is exposed to market risks related to currency fluctuations, which may impact its export operations[154]. Research and Development - The company has 37 new drug projects under research, with 3 in clinical research or BE stages and 13 submitted for production approval[48]. - The company applied for 29 invention patents during the reporting period, with 20 granted, bringing the total to 644 applications and 243 granted as of December 31, 2020[48]. - The company’s ADC innovative drug project ARX788 entered Phase II/III clinical trials for HER2-positive breast cancer in August 2020[48]. - The company’s R&D expenses increased by 21.24% to 546.09 million yuan, reflecting a commitment to innovation[51]. - The company is focusing on the development of new antibiotic drugs, including a new generation of fluoroquinolone antibiotics[97]. - The company is actively pursuing research and development in natural vitamin E and lutein products to expand its health product portfolio[99]. - The company has established two technical platforms in the field of vitamin products, focusing on green chemistry and microencapsulation of active ingredients[108]. - The company is actively pursuing the development of new products and technologies, including various antibiotic formulations[116]. Market and Product Development - The company operates in both animal and human nutrition sectors, with animal nutrition products primarily sold domestically and exported to Europe and America, while human nutrition products are sold through partnerships with large supplement and cosmetic companies[37]. - The vitamin industry shows steady low growth in demand, with significant price increases for key products like Vitamin E and A since March 2020 due to supply constraints exacerbated by the COVID-19 pandemic[37]. - The company has developed a range of specialized products, including fat-soluble vitamins and antibiotics, with significant market presence in domestic markets for its injectable products[41]. - The company is focusing on expanding its product line with high-purity teicoplanin and vancomycin injection solutions, which are crucial for treating severe infections[92]. - The company is committed to expanding its market reach through innovative product development and strategic partnerships in the pharmaceutical industry[92]. - The company is focusing on the market development of the innovative drug, Apixaban, and accelerating the clinical research of ARX788 in phases II/III[151]. - The health food segment is identified as a new profit growth point, with efforts to explore core competitiveness and implement professional and brand marketing strategies[151]. Sales and Revenue - The company achieved operating revenue of 732.69 million yuan, a year-on-year increase of 4.02%[51]. - Revenue from life nutrition products increased by 43.79% year-on-year, primarily due to significant price increases for vitamin E starting in March 2020 and an increase in vitamin A production[59]. - The pharmaceutical manufacturing segment reported sales of 203.70 million yuan, representing a year-on-year decrease of 18.54%[50]. - The total revenue for the company was approximately 7.29 billion CNY, with a year-on-year increase of 3.86%[57]. - Domestic sales revenue was approximately 5.03 billion CNY, with a year-on-year decrease of 4.00%[57]. - International sales revenue was approximately 2.27 billion CNY, reflecting a year-on-year increase of 26.93%[59]. Corporate Governance and Compliance - The audit report issued by Tianjian Accounting Firm was a standard unqualified opinion[5]. - The company has not faced any major litigation or arbitration matters during the reporting period[170]. - The company has not made any changes to its accounting firm during the reporting period, continuing with Tianjian Accounting Firm for the 2020 fiscal year[170]. - The company has not disclosed any employee stock ownership plans or other incentive measures during the reporting period[170]. - The company has not faced any risks of suspension or termination of its listing during the reporting period[170]. Social Responsibility and Community Engagement - The company donated a total of 400,000 RMB for targeted poverty alleviation efforts, including 100,000 RMB to support the construction of partnered villages and 300,000 RMB for assistance in other areas[187]. - The company plans to continue its targeted poverty alleviation initiatives by enhancing communication and cooperation with industry peers and social organizations, focusing on developing self-sustaining industries in impoverished areas[190]. - Zhejiang Pharmaceutical has invested over 160 million RMB in social welfare and established a dedicated charity foundation to support humanitarian aid[193]. - During the COVID-19 pandemic, the company donated 5.1 million RMB worth of anti-infection drugs and 1 million RMB in cash to affected areas, along with various medical supplies[193]. - The company has received multiple awards for its contributions to social responsibility, including the "2019 Chinese Pharmaceutical Enterprise Social Responsibility Leader Award"[193]. Environmental Responsibility - The company has implemented pollution control measures, ensuring all wastewater treatment systems are operational and compliant with environmental standards, with no instances of exceeding discharge limits reported[197]. - The company has established a stable waste treatment system, utilizing a new incineration facility to manage hazardous waste effectively[197]. - The company is committed to a sustainable development strategy, focusing on social responsibility and community support as part of its core values[193].